Kiadis Pharma announces FDA clearance of clinical study by The Ohio State University in R/R AML with off-the-shelf NK cells from universal donors

Amsterdam, The Netherlands, February 26, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, and The Ohio State University – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (“OSU” or “OSUCCC-James”), today announced the launch of a first-in-human clinical trial in patients with relapsed/refractory acute myeloid leukemia (R/R AML) with off-the-shelf Natural Killer (“NK”) cells manufactured using Kiadis’ FC21 mbIL21 feeder cells and proprietary universal donor platform. The trial is expected to provide further clinical proof-of-concept of Kiadis’ K-NK003 product.


By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...